Clinical Trial Update: A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial of RC18 (TACI-antibody fusion protein) in Primary Sjögren's Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• RC18 (RC18)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Primary Sjögren's Syndrome | Phase 2 | Status: COMPLETED